Literature DB >> 22044114

Biochemical and pharmacological characterization of nuclear urotensin-II binding sites in rat heart.

N D Doan1, T T M Nguyen, M Létourneau, K Turcotte, A Fournier, D Chatenet.   

Abstract

BACKGROUND AND PURPOSE During the past decade, a few GPCRs have been characterized at the nuclear membrane where they exert complementary physiological functions. In this study, we investigated (1) the presence of a functional urotensin-II (U-II) receptor (UT) in rat heart nuclear extracts and (2) the propensity of U-II and U-II-related peptide (URP) to cross the plasma membrane in a receptor-independent manner. EXPERIMENTAL APPROACH Biochemical and pharmacological methods including competitive binding assays, photoaffinity labelling, immunoblotting as well as de novo RNA synthesis were used to characterize the presence of functional UT receptors in rat heart nuclei. In addition, confocal microscopy and flow cytometry analysis were used to investigate the cellular uptake of fluorescent U-II and URP derivatives. KEY RESULTS The presence of specific U-II binding sites was demonstrated in rat heart nuclear extracts. Moreover, such subcellular localization was also observed in monkey heart extracts. In vitro transcription initiation assays on rat, freshly isolated, heart nuclei suggested that nuclear UT receptors are functional, and that U-II, but not URP, participates in nuclear UT-associated gene expression. Surprisingly, hU-II and URP efficiently crossed the plasma membrane in a receptor-independent mechanism involving endocytosis through caveolin-coated pits; this uptake of hU-II, but not that of URP, was dependent on extracellular pH. CONCLUSION Our results suggest that (1) U-II and URP can differentially modulate nuclear UT functions such as gene expression, and (2) both ligands can reach the internal cellular space through a receptor-independent mechanism.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22044114      PMCID: PMC3415652          DOI: 10.1111/j.1476-5381.2011.01710.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  48 in total

Review 1.  Role of urotensin II in health and disease.

Authors:  Bryan Ross; Katherine McKendy; Adel Giaid
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-05       Impact factor: 3.619

2.  pH (low) insertion peptide (pHLIP) inserts across a lipid bilayer as a helix and exits by a different path.

Authors:  Oleg A Andreev; Alexander G Karabadzhak; Dhammika Weerakkody; Gregory O Andreev; Donald M Engelman; Yana K Reshetnyak
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

Review 3.  Urotensin-II receptor modulators as potential drugs.

Authors:  Bruce E Maryanoff; William A Kinney
Journal:  J Med Chem       Date:  2010-04-08       Impact factor: 7.446

Review 4.  An update on nuclear calcium signalling.

Authors:  Martin D Bootman; Claire Fearnley; Ioannis Smyrnias; Fraser MacDonald; H Llewelyn Roderick
Journal:  J Cell Sci       Date:  2009-07-15       Impact factor: 5.285

5.  The vasoactive peptides urotensin II and urotensin II-related peptide regulate astrocyte activity through common and distinct mechanisms: involvement in cell proliferation.

Authors:  Marie Jarry; Mickaël Diallo; Céline Lecointre; Laurence Desrues; Tursonjan Tokay; David Chatenet; Jérôme Leprince; Oriana Rossi; Hubert Vaudry; Marie-Christine Tonon; Laurent Prézeau; Hélène Castel; Pierrick Gandolfo
Journal:  Biochem J       Date:  2010-04-28       Impact factor: 3.857

Review 6.  Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease.

Authors:  S A Douglas; E H Ohlstein
Journal:  Trends Cardiovasc Med       Date:  2000-08       Impact factor: 6.677

7.  Nuclear localization of cell-penetrating peptides is dependent on endocytosis rather than cytosolic delivery in CHO cells.

Authors:  Jennica L Zaro; Jacqueline E Vekich; Thuy Tran; Wei-Chiang Shen
Journal:  Mol Pharm       Date:  2009 Mar-Apr       Impact factor: 4.939

8.  Intracellular metabotropic glutamate receptor 5 (mGluR5) activates signaling cascades distinct from cell surface counterparts.

Authors:  Yuh-Jiin I Jong; Vikas Kumar; Karen L O'Malley
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

Review 9.  New insight into the molecular evolution of the somatostatin family.

Authors:  Hervé Tostivint; Isabelle Lihrmann; Hubert Vaudry
Journal:  Mol Cell Endocrinol       Date:  2008-03-06       Impact factor: 4.102

10.  Characterization of urotensin II, distribution of urotensin II, urotensin II-related peptide and UT receptor mRNAs in mouse: evidence of urotensin II at the neuromuscular junction.

Authors:  Christophe Dubessy; Dorthe Cartier; Benoît Lectez; Christine Bucharles; Nicolas Chartrel; Maïté Montero-Hadjadje; Patrice Bizet; David Chatenet; Hervé Tostivint; Elizabeth Scalbert; Jérome Leprince; Hubert Vaudry; Sylvie Jégou; Isabelle Lihrmann
Journal:  J Neurochem       Date:  2008-08-14       Impact factor: 5.372

View more
  6 in total

Review 1.  Fluorescent approaches for understanding interactions of ligands with G protein coupled receptors.

Authors:  Rajashri Sridharan; Jeffrey Zuber; Sara M Connelly; Elizabeth Mathew; Mark E Dumont
Journal:  Biochim Biophys Acta       Date:  2013-09-18

2.  Insights into the Molecular Determinants Involved in Urocontrin and Urocontrin A Action.

Authors:  Etienne Billard; David Chatenet
Journal:  ACS Med Chem Lett       Date:  2020-08-20       Impact factor: 4.345

3.  Discovery of new antagonists aimed at discriminating UII and URP-mediated biological activities: insight into UII and URP receptor activation.

Authors:  D Chatenet; M Létourneau; Q T Nguyen; N D Doan; J Dupuis; A Fournier
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

4.  Update on the urotensinergic system: new trends in receptor localization, activation, and drug design.

Authors:  David Chatenet; Thi-Tuyet M Nguyen; Myriam Létourneau; Alain Fournier
Journal:  Front Endocrinol (Lausanne)       Date:  2013-01-02       Impact factor: 5.555

5.  Intracellular Angiotensin-II Interacts With Nuclear Angiotensin Receptors in Cardiac Fibroblasts and Regulates RNA Synthesis, Cell Proliferation, and Collagen Secretion.

Authors:  Artavazd Tadevosyan; Jiening Xiao; Sirirat Surinkaew; Patrice Naud; Clémence Merlen; Masahide Harada; Xiaoyan Qi; David Chatenet; Alain Fournier; Bruce G Allen; Stanley Nattel
Journal:  J Am Heart Assoc       Date:  2017-04-05       Impact factor: 5.501

Review 6.  Insights into Nuclear G-Protein-Coupled Receptors as Therapeutic Targets in Non-Communicable Diseases.

Authors:  Salomé Gonçalves-Monteiro; Rita Ribeiro-Oliveira; Maria Sofia Vieira-Rocha; Martin Vojtek; Joana B Sousa; Carmen Diniz
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.